RxDoctor Payments Data

Pedram Ansari Pirsaraei, MD

Internal Medicine · Laguna Woods, CANPI 1871853614

Payments from drug & device makers

$1,068in general payments, 2019–2025

Across 45 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$177
  • Ardelyx, Inc.$173
  • Boehringer Ingelheim$121
  • Amgen$120
  • Novo Nordisk$113
  • Merck$77
  • plus $288 from 8 others

What the payments were for

  • Food & beverage$1,068100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,068 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$45,255
Medicare patients
154
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin62$94,748
EliquisApixaban36$41,870
JanuviaSitagliptin Phosphate18$20,288
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,750
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$4,676
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,908
SymbicortBudesonide/Formoterol Fumarate13$3,019
Atorvastatin Calcium359$2,931
Levothyroxine Sodium220$2,554
SynthroidLevothyroxine Sodium24$2,272
Rosuvastatin Calcium124$2,095
Losartan Potassium217$2,045
Albuterol Sulfate HfaAlbuterol Sulfate47$1,639
Gabapentin64$1,615
Amlodipine Besylate288$1,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$121$94,74862 claims
MerckJanuvia$77$20,28818 claims
GSKTrelegy Ellipta$54$16,75024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Laguna Woods

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →